GAINESVILLE, FL; January 20, 2017 – Captozyme Inc., a biotechnology company based in Gainesville, FL, recently raised $3.4 million. Captozyme plans to invest this money into the manufacturing and launch of Nephure, an oxalate-degrading enzyme to facilitate a low-oxalate diet.
“We are humbled by the confidence put in us to continue our research and develop products and aid us in getting these products to the marketplace,” says Aaron Cowley, CEO of Captozyme. “Our team has spent significant time and effort in making our products live up to the expectations of our most important stakeholders, the people who are currently struggling on a low-oxalate diet.”
A low-oxalate diet and normal consumption of calcium is useful in normalizing relatively high urinary oxalate. Sticking to the diet can be hard, especially when there can be a wide range of discrepancies online about what food is generally considered oxalate rich. Nephure’s goal is to make being healthier, easier; it takes away this uncertainty by breaking down the oxalate compound in food.
A low-oxalate diet should limit oxalate intake to 40 to 50 mg each day, though in the USA oxalate intake is estimated to average 150-200 mg each day. Captozyme’s pre-clinical data of Nephure features:
- 40-60% reduction in urinary oxalate when administered to dogs with high urinary oxalate
- Successful creation of oxalate-free craft beer and ready to drink tea and juices
Captozyme is a biotechnology company that is dedicated to helping people better manage their diets and overall health. Through Nephure they have created a product that allows people to enjoy the food they love without the consequences of adding oxalate to their body. Learn more about Captozyme at Captozyme.com and stay up to date on Nephure for when it launches in the summer.